Pedro Silva

Dr. Pedro Silva

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Tuberculosis
Verified
Journal Article
Closed access
CBCaroline Busatto
Caroline Busatto
JVJulia Silveira Vianna
Julia Silveira Vianna
LSLande Vieira da Silva
Lande Vieira da Silva
IRIvy Bastos Ramis
Ivy Bastos Ramis
PSPedro Silva
Pedro Silva

18 September 2019 in Antibiotics
Verified
Journal Article
Open access
PDF file
JVJulia Silveira Vianna
Julia Silveira Vianna
DMDiana Machado
Diana Machado
IRIvy B. Ramis
Ivy B. Ramis
FSFábia P. Silva
Fábia P. Silva
DBDienefer V. Bierhals
Dienefer V. Bierhals
PSPedro Silva
Pedro Silva
The basis of drug resistance in Mycobacterium abscessus is still poorly understood. Nevertheless, as seen in other microorganisms, the efflux of antimicrobials may also play a role in M. abscessus drug resistance. Here, we investigated the role of efflux pumps in clarithromycin resistance using nine clinical isolates of M. abscessus complex belonging to the T28 erm(41) sequevar responsible for the inducible resistance to clarithromycin. The strains were characterized by drug susceptibility testing in the presence/absence of the efflux inhibitor verapamil and by genetic analysis of drug-resistance-associated genes. Efflux activity was quantified by real-time fluorometry. Efflux pump gene expression was studied by RT-qPCR upon exposure to clarithromycin. Verapamil increased the susceptibility to clarithromycin from 4- to ≥64-fold. The efflux pump genes MAB_3142 and MAB_1409 were found consistently overexpressed. The results obtained demonstrate that the T28 erm(41) polymorphism is not the sole cause of the inducible clarithromycin resistance in M. abscessus subsp. abscessus or bolletii with efflux activity providing a strong contribution to clarithromycin resistance. These data highlight the need for further studies on M. abscessus efflux response to antimicrobial stress in order to implement more effective therapeutic regimens and guidance in the development of new drugs against these bacteria.

20 January 2010 in Pharmaceutical Biology
Verified
Journal Article
Open access
PDF file
DRDaniela Ramos
Daniela Ramos
PSPedro Silva
Pedro Silva
Tuberculosis remains a serious public health problem, with nine million cases being reported annually. Treatment with antibiotics is the most effective mechanism to control this disease, although the increase in cases with resistant strains, co-infection with HIV, and the long duration of treatment has established the need to develop new drugs. Here we show the activity of usnic acid against susceptible and resistant Mycobacterium tuberculosis strains and against nontuberculous mycobacteria. Further, we did not identify any contribution of efflux in innate resistance to usnic acid.

3 March 2018 in Antibiotics
Verified
Journal Article
Open access
PDF file
DMDiana Machado
Diana Machado
João PerdigãoJoão Perdigão
João Perdigão
IPIsabel Portugal
Isabel Portugal
MPMARCO PIERONI
MARCO PIERONI
PSPedro Silva
Pedro Silva
MVMiguel Viveiros
Miguel Viveiros
With the growing body of knowledge on the contribution of efflux activity to Mycobacterium tuberculosis drug resistance, increased attention has been given to the use of efflux inhibitors as adjuvants of tuberculosis therapy. Here, we investigated how efflux activity modulates the levels of efflux between monoresistant and multi- and extensively drug resistant (M/XDR) M. tuberculosis clinical isolates. The strains were characterized by antibiotic susceptibility testing in the presence/absence of efflux inhibitors, molecular typing, and genetic analysis of drug-resistance-associated genes. Efflux activity was quantified by real-time fluorometry. The results demonstrated that all the M. tuberculosis clinical strains, susceptible or resistant, presented a faster, rapid, and non-specific efflux-mediated short-term response to drugs. The synergism assays demonstrated that the efflux inhibitors were more effective in reducing the resistance levels in the M/XDR strains than in the monoresistant strains. This indicated that M/XDR strains presented a more prolonged response to drugs mediated by efflux compared to the monoresistant strains, but both maintain it as a long-term stress response. This work shows that efflux activity modulates the levels of drug resistance between monoresistant and M/XDR M. tuberculosis clinical strains, allowing the bacteria to survive in the presence of noxious compounds.

1 March 2017 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
LSLande Silva
Lande Silva
LCLillian Lucas Carrion
Lillian Lucas Carrion
AGAndrea von Groll
Andrea von Groll
SCSofia Costa
Sofia Costa
EJElisabete Junqueira
Elisabete Junqueira
PSPedro Silva
Pedro Silva

1 January 2015 in Journal of Venomous Animals and Toxins including Tropical Diseases
Verified
Journal Article
Open access
DRDaniela Ramos
Daniela Ramos
AMAlexandre Matthiensen
Alexandre Matthiensen
WCWilson Colvara
Wilson Colvara
AVAna de Votto
Ana de Votto
GTGilma Trindade
Gilma Trindade
JYJoão Yunes
João Yunes
The present work aimed to evaluate the antimycobacterial activity and cytotoxicity of Microcystis aeruginosa toxins, the MC-LR variant and purified extract of [D-Leu1] microcystin-LR. The antimicrobial activity of M. aeruginosa extract and microcystin was evaluated by resazurin microtiter assay against Mycobacterium tuberculosis, M. terrae, M. chelonae and M. kansasii. The cytotoxicity assay was performed by trypan blue exclusion against the HTC cell line. Antimicrobial activity was observed in the hexanic extract of M. aeruginosa (RST 9501 strain) against M. tuberculosis, including sensitive and resistant strains with minimal inhibitory concentrations (MIC) between 1.93 μM and 0.06 μM. The high activity of M. aeruginosa hexanic extract could be attributed to the major presence of the toxins MC-LR and [D-Leu1] MC-LR that showed activity at MIC between 53 and 0.42 μM against tested mycobacterial strains. Even at the highest concentration tested, no toxicity of M. aeruginosa extracts was identified against HTC cells. These preliminary results suggest that [D-Leu1] MC-LR is a promising candidate for the development of a new antimycobacterial agent.